Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.


Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
11 2020
Historique:
received: 14 08 2019
revised: 29 01 2020
accepted: 29 01 2020
pubmed: 3 3 2020
medline: 17 4 2021
entrez: 2 3 2020
Statut: ppublish

Résumé

The HBV HBx regulatory protein is required for transcription from the covalently closed circular DNA (cccDNA) minichromosome and affects the epigenetic control of both viral and host cellular chromatin. We explored, in relevant cellular models of HBV replication, the functional consequences of HBx interaction with DLEU2, a long non-coding RNA (lncRNA) expressed in the liver and increased in human hepatocellular carcinoma (HCC), in the regulation of host target genes and the HBV cccDNA. We show that HBx binds the promoter region, enhances the transcription and induces the accumulation of DLEU2 in infected hepatocytes. We found that nuclear DLEU2 directly binds HBx and the histone methyltransferase enhancer of zeste homolog 2 (EZH2), the catalytic active subunit of the polycomb repressor complex 2 (PRC2) complex. Computational modelling and biochemical evidence suggest that HBx and EZH2 share two preferential binding sites in DLEU2 intron 1. HBx and DLEU2 co-recruitment on the cccDNA displaces EZH2 from the viral chromatin to boost transcription and viral replication. DLEU2-HBx association with target host promoters relieves EZH2 repression and leads to the transcriptional activation of a subset of EZH2/PRC2 target genes in HBV-infected cells and HBV-related HCCs. Our results highlight the ability of HBx to bind RNA to impact on the epigenetic control of both viral cccDNA and host genes and provide a new key to understand the role of DLEU2 and EZH2 overexpression in HBV-related HCCs and HBx contribution to hepatocytes transformation.

Identifiants

pubmed: 32114505
pii: gutjnl-2019-319637
doi: 10.1136/gutjnl-2019-319637
pmc: PMC7569396
doi:

Substances chimiques

DLEU2 lncRNA, human 0
DNA, Circular 0
RNA, Long Noncoding 0
Trans-Activators 0
Viral Regulatory and Accessory Proteins 0
hepatitis B virus X protein 0
EZH2 protein, human EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2016-2024

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Biosci Rep. 2019 Mar 22;39(3):
pubmed: 30837324
J Mol Biol. 2007 Sep 14;372(2):549-61
pubmed: 17681540
Cold Spring Harb Perspect Med. 2016 Jan 08;6(3):a021402
pubmed: 26747833
Hepatology. 2017 Oct;66(4):1296-1313
pubmed: 28762522
BMC Genomics. 2017 Feb 17;18(1):184
pubmed: 28212627
Nat Commun. 2017 Feb 13;8:14421
pubmed: 28194035
Gastroenterology. 2006 Mar;130(3):823-37
pubmed: 16530522
Mol Cell. 2017 Mar 16;65(6):1056-1067.e5
pubmed: 28306504
Oncogene. 2016 Feb 11;35(6):715-26
pubmed: 25893293
Mol Cell. 2011 Sep 16;43(6):904-14
pubmed: 21925379
PLoS One. 2013 Dec 19;8(12):e84147
pubmed: 24367637
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Mol Cell. 2015 Jan 22;57(2):304-316
pubmed: 25578878
Nature. 2016 Mar 17;531(7594):386-9
pubmed: 26983541
Oncogene. 2017 May 25;36(21):2991-3001
pubmed: 28068325
Genes Dev. 2010 Feb 15;24(4):368-80
pubmed: 20123894
Genome Res. 2016 Jul;26(7):896-907
pubmed: 27197219
Nat Methods. 2016 Dec 29;14(1):5-6
pubmed: 28032625
Gastroenterology. 2016 Nov;151(5):986-998.e4
pubmed: 27453547
PLoS One. 2014 Dec 11;9(12):e114917
pubmed: 25503252
Mol Cell. 2010 Dec 22;40(6):939-53
pubmed: 21172659
Carcinogenesis. 2018 Jul 30;39(8):1016-1025
pubmed: 29796634
J Hepatol. 2011 Nov;55(5):996-1003
pubmed: 21376091
Nature. 2011 Jan 20;469(7330):343-9
pubmed: 21248841
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3098-103
pubmed: 24516139
Nat Chem Biol. 2013 Oct;9(10):643-50
pubmed: 23974116
Cell Signal. 2014 Dec;26(12):2606-13
pubmed: 25152375
Bioinformatics. 2008 Sep 1;24(17):1865-73
pubmed: 18591193
Nat Commun. 2019 Apr 11;10(1):1679
pubmed: 30976011
Sci Rep. 2016 Mar 24;6:23521
pubmed: 27009634
Nature. 2010 Apr 15;464(7291):1071-6
pubmed: 20393566
Nat Struct Mol Biol. 2019 Mar;26(3):237-247
pubmed: 30833789
Gut. 2016 May;65(5):861-9
pubmed: 25666192
Nat Struct Mol Biol. 2012 Jun 03;19(7):664-70
pubmed: 22659877
Science. 2017 Nov 24;358(6366):1051-1055
pubmed: 29074580
Hepatology. 2012 Oct;56(4):1240-51
pubmed: 22505317
Mol Syst Biol. 2011 Feb 15;7:469
pubmed: 21326236
J Mol Biol. 2016 Feb 22;428(4):720-725
pubmed: 26410586
J Mol Biol. 2017 Jun 30;429(13):1978-1993
pubmed: 27742591
Exp Cell Res. 2009 Oct 15;315(17):2941-52
pubmed: 19591824
Mol Cell. 2015 Feb 5;57(3):552-8
pubmed: 25601759
PLoS One. 2014 May 20;9(5):e97725
pubmed: 24846307
Front Cell Infect Microbiol. 2017 May 26;7:205
pubmed: 28603696
Hepatology. 2017 Aug;66(2):398-415
pubmed: 28236308
J Hepatol. 2015 Nov;63(5):1093-102
pubmed: 26143443
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19975-9
pubmed: 19906987
Nat Struct Mol Biol. 2010 Jan;17(1):105-11
pubmed: 19966799
Virus Res. 2016 Jan 2;212:103-13
pubmed: 26239319
Viruses. 2014 Nov 24;6(11):4683-702
pubmed: 25421893
Cell. 2014 Nov 6;159(4):869-83
pubmed: 25417162
Gut. 2011 Jul;60(7):967-76
pubmed: 21330577
J Hepatol. 2017 Oct;67(4):847-861
pubmed: 28778687
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Hepatology. 2016 Oct;64(4):1033-48
pubmed: 27338022
Semin Liver Dis. 2017 Aug;37(3):231-242
pubmed: 28847034

Auteurs

Debora Salerno (D)

Center for Life NanoScience@Sapienza, Istituto Italiano di Tecnologia, Rome, Italy.

Letizia Chiodo (L)

Department of Engineering, Campus Bio-Medico University, Rome, Italy.

Vincenzo Alfano (V)

Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France.

Oceane Floriot (O)

Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France.

Grazia Cottone (G)

Department of Physics and Chemistry - Emilio Segre', University of Palermo, Palermo, Italy.

Alexia Paturel (A)

Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France.

Matteo Pallocca (M)

SAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Marie-Laure Plissonnier (ML)

Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France.

Safaa Jeddari (S)

Department of Internal Medicine (DMISM), Sapienza University, Rome, Italy.

Laura Belloni (L)

Department of Internal Medicine (DMISM), Sapienza University, Rome, Italy.

Mirjam Zeisel (M)

Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France.

Massimo Levrero (M)

Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France fraguerrieri@gmail.com massimo.levrero@inserm.fr.
Department of Internal Medicine (DMISM), Sapienza University, Rome, Italy.

Francesca Guerrieri (F)

Center for Life NanoScience@Sapienza, Istituto Italiano di Tecnologia, Rome, Italy fraguerrieri@gmail.com massimo.levrero@inserm.fr.
Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH